Eckert & Ziegler Strahlen und Medizintechnik AG
XETRA:EUZ

Watchlist Manager
Eckert & Ziegler Strahlen und Medizintechnik AG Logo
Eckert & Ziegler Strahlen und Medizintechnik AG
XETRA:EUZ
Watchlist
Price: 50.75 EUR 4.42% Market Closed
Market Cap: 1.1B EUR
EUZ
/
Income Statement
/
Revenue

Eckert & Ziegler Strahlen und Medizintechnik AG
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Eckert & Ziegler Strahlen und Medizintechnik AG
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Eckert & Ziegler Strahlen und Medizintechnik AG
XETRA:EUZ
Revenue
€277.7m
CAGR 3-Years
15%
CAGR 5-Years
9%
CAGR 10-Years
8%
Carl Zeiss Meditec AG
XETRA:AFX
Revenue
€2.1B
CAGR 3-Years
7%
CAGR 5-Years
-1%
CAGR 10-Years
8%
Stratec SE
XETRA:SBS
Revenue
€250.5m
CAGR 3-Years
-5%
CAGR 5-Years
3%
CAGR 10-Years
6%
Siemens Healthineers AG
XETRA:SHL
Revenue
€22.7B
CAGR 3-Years
6%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Draegerwerk AG & Co KGaA
XETRA:DRW8
Revenue
€3.3B
CAGR 3-Years
-2%
CAGR 5-Years
4%
CAGR 10-Years
3%
Sartorius AG
XETRA:SRT
Revenue
€3.4B
CAGR 3-Years
-1%
CAGR 5-Years
13%
CAGR 10-Years
14%

Eckert & Ziegler Strahlen und Medizintechnik AG
Glance View

Market Cap
1.1B EUR
Industry
Health Care

Eckert & Ziegler Strahlen- und Medizintechnik AG engages in the provision of isotope technology for medical, scientific, and industrial use. The company is headquartered in Berlin, Berlin and currently employs 866 full-time employees. The company went IPO on 2008-02-25. The firm operates through three segments: Radiation Therapy, Isotope Products and Radiopharma. The Radiation Therapy segment operates through Eckert & Ziegler BEBIG and produces and distributes medical products for the treatment of cancer using brachytherapy. The Isotope Products segment provides sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration and environmental monitoring sources and solutions, as well as bulk radioisotopes for pharmaceutical, therapeutic and industrial product manufacturers. The Radiopharma segment specializes in molecular imaging and nuclear medicine, and supplies various radiopharmaceuticals, radiochemicals and related equipment.

EUZ Intrinsic Value
57.23 EUR
Undervaluation 11%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is Eckert & Ziegler Strahlen und Medizintechnik AG's Revenue?
Revenue
277.7m EUR

Based on the financial report for Sep 30, 2024, Eckert & Ziegler Strahlen und Medizintechnik AG's Revenue amounts to 277.7m EUR.

What is Eckert & Ziegler Strahlen und Medizintechnik AG's Revenue growth rate?
Revenue CAGR 10Y
8%

Over the last year, the Revenue growth was 15%. The average annual Revenue growth rates for Eckert & Ziegler Strahlen und Medizintechnik AG have been 15% over the past three years , 9% over the past five years , and 8% over the past ten years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 246,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.